Eugene Pacelli Mccague Sells 3,255 Shares of Icon (NASDAQ:ICLR) Stock

Key Points

• Icon director Eugene Pacelli Mccague sold 3,255 shares at an average price of $175, generating $569,625 and reducing his stake by 46.07% to 3,811 shares. He also sold 841 shares in August.
• Icon shares opened at $169.68, down 2.4%, with a market capitalization of approximately $12.99 billion. The stock has traded between $66.57 and $203.91 over the past year.
• Icon exceeded quarterly expectations with earnings of $2.56 per share and revenue of $2.06 billion, while institutional investors own 95.61% of the stock. Analysts’ consensus rating is “Hold”, with an average price target of $170.40.

Icon Plc (NASDAQ:ICLR - Get Free Report) Director Eugene Mccague sold 3,255 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $175.00, for a total value of $569,625.00. Following the completion of the transaction, the director owned 3,811 shares in the company, valued at $666,925. This represents a 46.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Eugene Pacelli Mccague also recently made the following trade(s):

• On Tuesday, August 11th, Eugene Mccague sold 841 shares of Icon stock. The shares were sold at an average price of $164.29, for a total value of $138,167.89.

Icon Stock Down 2.4%

Shares of ICLR stock opened at $169.68 on Friday. The company has a market capitalization of $12.99 billion, a price-to-earnings ratio of 39.83, a PEG ratio of 8.03 and a beta of 1.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The stock's 50 day simple moving average is $167.27 and its 200 day simple moving average is $140.01. Icon Plc has a twelve month low of $66.57 and a twelve month high of $203.91.

Icon (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, topping analysts' consensus estimates of $2.55 by $0.01. The business had revenue of $2.06 billion during the quarter, compared to analysts' expectations of $2 billion. Icon had a net margin of 3.99% and a return on equity of 8.02%. Icon's revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $3.26 earnings per share. As a group, research analysts predict that Icon Plc will post 9.58 EPS for the current year.

Institutional Trading of Icon

A number of hedge funds and other institutional investors have recently made changes to their positions in ICLR. Capital World Investors lifted its position in shares of Icon by 555.2% during the fourth quarter. Capital World Investors now owns 1,496,479 shares of the medical research company's stock worth $272,688,000 after purchasing an additional 1,268,095 shares in the last quarter. Lyrical Asset Management LP bought a new stake in shares of Icon during the fourth quarter valued at approximately $176,382,000. Norges Bank acquired a new stake in shares of Icon in the fourth quarter valued at approximately $160,073,000. Maple Rock Capital Partners Inc. increased its holdings in shares of Icon by 257.8% in the second quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company's stock valued at $208,383,000 after purchasing an additional 864,300 shares in the last quarter. Finally, Van Lanschot Kempen Investment Management N.V. bought a new position in Icon in the 4th quarter worth approximately $135,489,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on ICLR shares. Mizuho boosted their price objective on shares of Icon from $180.00 to $190.00 and gave the stock an "outperform" rating in a report on Friday, June 26th. Royal Bank Of Canada upgraded Icon from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. BMO Capital Markets boosted their price target on shares of Icon from $160.00 to $187.00 and gave the company an "outperform" rating in a report on Thursday, June 25th. William Blair upgraded shares of Icon to a "strong-buy" rating in a research report on Thursday, July 30th. Finally, Leerink Partners set a $145.00 price target on shares of Icon in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $170.40.

About Icon

ICON plc is a contract research and development organization that provides services to pharmaceutical, biotechnology, medical device and government clients. The company helps sponsors plan, manage and execute clinical development programs, supporting the progression of new medicines and healthcare products from early research through regulatory approval and commercialization.

Its services include clinical trial design and management, clinical data management, biostatistics, pharmacovigilance, regulatory consulting, medical affairs, laboratory services and real-world evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.